imrecoxib (BAP 909) / Jiangsu Hengrui Pharma - LARVOL DELTA

Herbal analgesic patches versus NSAIDs in soft tissue injury management: real-world comparative effectiveness from a 35-center chinese prospective cohort of 1378 participants. (PubMed, Int J Surg) - "GTP is a safe NSAIDs alternative, especially for patients with comorbidities. Monotherapy or a 2-week SCI-to-GTP transition is recommended because of the lack of combination synergy."

HEOR • Journal • Real-world evidence • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Analgesic application of a novel non-steroidal anti-inflammatory drug imrecoxib after total knee arthroplasty: a prospective randomized controlled study. (PubMed, Perioper Med (Lond)) - P4 | "Our prospective randomized controlled trial demonstrates that imrecoxib can effectively alleviate postoperative pain after TKA, reduce opioid dosage, and does not cause additional adverse reactions, providing a new option for analgesic treatment after TKA."

Journal • Orthopedics • Pain • CRP • IL6

Imrecoxib attenuates osteoarthritis by modulating synovial macrophage polarization through inactivating COX-2/PGE2 signaling pathway. (PubMed, Front Bioeng Biotechnol) - "Furthermore, Imrecoxib regulates macrophage polarization through the COX-2/PGE2 pathway. This study unravels that Imrecoxib protects joint cartilage and attenuates osteoarthritis by modulating synovial macrophage polarization through inactivating COX-2/PGE2 signaling pathway, providing new drug delivery strategy for the clinical treatment of OA."

Journal • Immunology • Inflammation • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial. (PubMed, Gut) - "Parecoxib sequential with imrecoxib was effective and well tolerated in reducing the occurrence and duration of SAP and local complications through suppression of systemic inflammatory response, leading to decreased morbidity."

Journal • Immunology • Inflammation • Pancreatitis • Systemic Inflammatory Response Syndrome

Prognostic Impact and Safety of Ketorolac Tromethamine in Tibial Plateau Fracture Patients Undergoing Open Reduction and Internal Fixation. (PubMed, Ann Ital Chir) - "The combination of ketorolac tromethamine and imrecoxib was more effective than imrecoxib alone in alleviating postoperative pain in TPF patients undergoing ORIF. Ketorolac tromethamine had no significant impact on bone healing, indicating its potential as bone-safe analgesia when combined with imrecoxib."

Journal • Retrospective data • Anesthesia • Musculoskeletal Diseases • Orthopedics • Pain • B2M • BGLAP

Imrecoxib: Advances in Pharmacology and Therapeutics. (PubMed, Drug Des Devel Ther) - "From a safety point of view, imrecoxib showed adverse effects common to NSAIDs; however, it has lower incidence of new-onset hypertension than other types of selective COX-2 inhibitors, less gastrointestinal toxicities than non-selective NSAIDs, weaker risk of drug interaction than celecoxib, and more suitable for elderly patients due to balanced inhibition of COX-1/COX-2. In the field of osteoarthritis treatment, mechanisms other than the analgesic and anti-inflammatory effects of COX-2 inhibitors are also being explored. Taken together, imrecoxib is a moderate selective COX-2 inhibitor with some advantages, and there would be more clinical applications and research opportunities in the future."

Journal • Review • Ankylosing Spondylitis • Cardiovascular • Colon Cancer • Colorectal Cancer • Dermatology • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Disorder • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Osteoarthritis • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis

PREVENTION AND TREATMENT OF SEVERE ACUTE PANCREATITIS WITH CYCLOOXYGENASE-2 INHIBITORS -- AN INVESTIGATOR-INITIATED, PROSPECTIVE, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL (DDW 2024) - "Conclusions Sequential administration of parecoxib and imrecoxib effectively decreased the occurrence of SAP and was beneficial for the treatment of SAP through their anti-inflammatory action. Early use of COX-2-I after AP onset presented better effects of prevention and treatment of SAP."

Clinical • Gastroenterology • Gastrointestinal Disorder • Pancreatitis

Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis. (PubMed, Rheumatol Ther) - "This study successfully identified biomarkers for evaluating imrecoxib's clinical response in patients with OA using 4D-DIA technology. These biomarkers may play a vital role in future personalized OA treatment strategies, pending further confirmation."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • LGALS1 • LGALS3

Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice. (PubMed, Heliyon) - "From Day 0 to Day 13, the mice were orally administered imrecoxib (100 mg/kg) and pirfenidone (200 mg/kg) daily, and from Day 7 to Day 13, the mice were orally administered pirfenidone and imrecoxib daily. The changes in the expression of related proteins in mouse lung tissue were similar to those in cells. In summary, our findings suggested that the administration of imrecoxib prevented and treated murine IPF by inhibiting inflammation and the TGF-β1-ERK1/2 signaling pathway."

Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CTGF • FN1 • TGFB1 • TNFA

Effectiveness of preemptive analgesia with imrecoxib on analgesia after anterior cruciate ligament reconstruction: a randomized controlled study (PubMed, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi) - "And there was no significant difference in Lysholm scores between the groups at 1, 3, 6, and 12 months after operation (P>0.05). Compared with the traditional analgesic scheme, applying the concept of preemptive analgesia with imrecoxib to manage the perioperative pain of ACL reconstruction can effectively reduce the early postoperative pain, reduce the dosage of opioids, and promote the early recovery of limb function."

Journal • Anesthesia • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology • Thrombosis • Venous Thromboembolism

Evaluation of the clinical effect of acupuncture in treatment of neck pain in cervical spondylosis based on propensity score matching (PubMed, Zhongguo Zhen Jiu) - "Acupuncture is effective and safe in the relief of neck pain and the improvement of comprehensive quality of life in the patients with cervical spondylosis."

Journal • Musculoskeletal Pain • Pain

Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study. (PubMed, Inflammopharmacology) - "Imrecoxib is non-inferior to celecoxib for postoperative analgesia in hip osteoarthritis patients undergoing THA."

Head-to-Head • Journal • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. (PubMed, Clin Rheumatol) - "Imrecoxib and celecoxib affect SIJ inflammation, disease activity, and the course of disease by regulating bone metabolism and angiogenesis in axSpA. Key Points •After treatment with imrecoxib and celecoxib, the levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased, correlating with the course of disease, disease activity, and SIJ inflammation. • A decrease in ESR was significantly correlated with a decrease in the levels of RUNX2 and SIJ inflammation. • The levels of sclerostin were more significantly elevated in SIJ inflammation remission group. •Imrecoxib and celecoxib affect SIJ inflammation by regulating bone metabolism and angiogenesis in axSpA."

Journal • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Osteoarthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CTNNB1 • DKK1 • RUNX2 • TNFRSF11B

Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects. (PubMed, Drug Des Devel Ther) - "Imrecoxib was well tolerated in both non-elderly and elderly healthy subjects, especially with favorable gastrointestinal and cardiovascular safety profiles. Pharmacokinetic and safety profiles of imrecoxib in elderly healthy subjects indicated that no dose adjustment should be required for elderly population."

Journal • PK/PD data • Cardiovascular • Gastrointestinal Disorder • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis. (PubMed, Drug Des Devel Ther) - "The efficacy of imrecoxib and celecoxib in the treatment of axSpA is equivalent. Also, they have the same efficacy after being combined with TNFi."

Journal • Real-world evidence • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Inhibition of imrecoxib on mRNA and protein expression of CYP2C11 enzyme in rats. (PubMed, Biomed Chromatogr) - "Imrecoxib can reduce mRNA and protein expression of CYP2C11 enzyme in rat liver and inhibit the activity of CYP2C11 enzyme in a dose-dependent manner. However, it will not produce clinically significant drug interactions."

Journal • Preclinical

Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study. (PubMed, Inflammopharmacology) - "Imrecoxib is non-inferior to celecoxib in postoperative analgesia and exhibits an acceptable tolerance in patients undergoing AKS."

Head-to-Head • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Orthopedics • Pain

Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial. (PubMed, J Ethnopharmacol) - "FSGTC alone or combined with NSAIDs has therapeutic efficacy in decreasing disease activity of active AS patients and with good gastrointestinal tolerability after 4-week of treatment."

Clinical • Journal • Ankylosing Spondylitis • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • Seronegative Spondyloarthropathies • CRP

Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis. (PubMed, Ann Transl Med) - "Although there were uncertainties, imrecoxib was the more cost-effective option compared to celecoxib, with a definite possibility. Due to the limitations of the original model and this study, the results of this study should be adopted with caution."

Clinical • HEOR • Journal • Cardiovascular • Immunology • Myocardial Infarction • Osteoarthritis • Pain • Rheumatology

Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial. (PubMed, Ann Transl Med) - "No perioperative complications were observed in the imrecoxib group during the 24-hour period after the first dose. Imrecoxib could significantly relieve pain and has a non-inferior analgesic efficacy compared to celecoxib with good tolerance following oral surgery."

Clinical • Head-to-Head • Journal • Pain

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis. (PubMed, Cost Eff Resour Alloc) - "The addition of a proton pump inhibitor to both imrecoxib and diclofenac was advised. Imrecoxib provides a valuable option for patients with osteoarthritis. Uncertainties existed in the model, and the suggestions can be adopted with caution."

Clinical • HEOR • Journal • Cardiovascular • Gastrointestinal Disorder • Immunology • Osteoarthritis • Pain • Rheumatology

The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis. (PubMed, Ann Palliat Med) - "In respect of the at-risk patients (i.e., those with related disease, such as GI complications, CV events or other risks), the patterns with which oral NSAIDs were prescribed was not standardized. In terms of adverse effects, selective COX-2 inhibitors represent a better choice than traditional NSAIDs and NSAID combinations."

Clinical • Journal • Cardiovascular • Gastrointestinal Disorder • Hypertension • Orthopedics

Imrecoxib Inhibits Paraquat-Induced Pulmonary Fibrosis through the NF-κB/Snail Signaling Pathway. (PubMed, Comput Math Methods Med) - "Imrecoxib can inhibit EMT of paraquat-induced A549 cells and alleviate paraquat-caused pulmonary fibrosis through the NF-κB/snail signal pathway. Therefore, imrecoxib is a drug worthy of study in the treatment of paraquat-induced pulmonary fibrosis."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases

Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. (PubMed, Sci Rep) - "The 90% CIs of the GMRs of AUC C and INR were all within a 0.8-1.25 interval. The combination of warfarin and imrecoxib did not impact the pharmacodynamics and pharmacokinetics of single-dose warfarin; therefore, when treating a patient with imrecoxib and warfarin, it is not required to adjust the dosage of warfarin."

Clinical • Journal • PK/PD data • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Dose Investigation of Imrecoxib in Patients with Renal Insufficiency Based on Modelling and Simulation. (PubMed, Eur J Pharm Sci) - "Conclusion A PPK model of imrecoxib and its two metabolites is presented. The renal insufficiency regimen should be reduced to '75 mg q12h' or '50 mg q8h'."

Clinical • Journal • Renal Disease